All In MedTech

Device Trial Radar · NCT06146231

Motiva Flora® Aesthetic Breast Recon® Clinical Study

Motiva Flora® Tissue Expander as a Support for the Creation of an Autologous Adipose Matrix for Hybrid Breast Reconstruction: a Pivotal Study

Last checked: Nov 20, 2026Latest source record: Nov 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingTitle says "pivotal". This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

66

Planned (sponsor's estimate)

Start

Aug 18, 2023

Primary completion

Apr 2026

Study completion Apr 2027

Sponsor

Lead sponsor
Establishment LabsPublic (ESTA)
Sponsor type
Industry
Collaborators
NAMSA
First posted
Nov 24, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated device
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The present study will be based on a hybrid breast reconstruction approach with initial skin expansion using the Motiva Flora® Tissue Expander followed by a serial fat grafting session and a final step that includes the placement of a permanent breast implant Ergonomix2®.

Conditions

  • Mammaplasty
  • Breast Cancer
  • Poland Syndrome

Interventions

  • Motiva Flora® Tissue ExpanderDevice

    This hybrid breast reconstruction involves a stage in which the tissue expander (Motiva Flora®) is used as intended for a conventional expansion. After achieving the desired volume, it is deflated in a controlled way to proceed with the execution of serial fat grafting procedures (reverse expansion). This also means the expander is implanted longer than indicated on its current Directions For Use. Once the reverse expansion is complete, the expander is replaced with a long-term breast implant. Motiva Implants Ergonomix2® Sterile Silicone Breast Implants will be used as per Standard of Care under the CE marked indication. To obtain the safest, most natural, and aesthetic outcomes, Ergonomix2® breast implants have been selected as the standard silicone breast implants for this study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total adverse envent rateTime frame: 46 months

Locations

4 sites in 4 countries. Site status is shown where the registry gives one.

  • Universitair Ziekenhuis Gent

    Ghent, Belgium · Recruiting

  • Hospital Universitario San Ignacio

    Bogotá, Colombia · Not yet recruiting

  • Hospital UNIBE

    San José, Costa Rica · Not yet recruiting

1 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.